A new drug for Alzheimer’s is struggling to justify its price

JAY REINSTEIN remembers where he was when he heard that the Food and Drug Administration (FDA) had approved Aduhelm (aducanumab), a new Alzheimer’s drug. It was last June, and he was at Kohl’s, a department store, when he started getting news alerts on his phone. He asked a stranger outside the shop to take a picture of him jumping into the air, which he promptly posted on Facebook to share the news with family and friends. “It was an awesome feeling because it really felt like there was hope for me and so many others,” he says. “I remember going home, and my wife was crying.”